Assess Safety Risk Control
Evaluate whether adverse event information is identified, processed, medically reviewed, reported and escalated in a timely and controlled manner.
Back to Inspection & Audit
Good Pharmacovigilance Practice Auditing
GVP Audits
Independent, risk-based pharmacovigilance audits for marketing authorization holders, sponsors, biotechnology companies, service providers and global safety organizations seeking stronger patient safety governance, reliable safety data, effective oversight and inspection-ready pharmacovigilance systems.
Service Overview
Independent Assurance Across the Pharmacovigilance System
GVP audits assess whether safety information is collected, evaluated, reported, escalated and governed through a controlled system that supports patient protection, regulatory compliance and effective benefit-risk management.
Confirm Completeness and Traceability
Review case records, source documentation, system data, reconciliation activities and quality controls supporting reliable safety evidence.
Evaluate Accountability and Control
Assess whether responsibilities across internal teams, affiliates, partners and vendors are clearly defined, monitored and supported by documented oversight.
Common Pharmacovigilance Risks
Where Safety Systems Commonly Lose Control
Pharmacovigilance risk often develops where responsibilities are fragmented, safety data is incomplete, vendors are not adequately overseen or quality signals are not escalated through a controlled governance process.
Late or Incomplete Case Processing
Adverse event information is not captured, followed up, medically reviewed or submitted within required timelines.
Weak Signal Management
Potential safety signals are not identified, validated, prioritized, documented or escalated consistently.
Insufficient Vendor and Partner Oversight
Delegated pharmacovigilance activities are not supported by clear responsibilities, performance monitoring, reconciliation and escalation.
Inadequate Quality System Control
Deviations, CAPAs, training, procedures, audits and management review do not provide sufficient evidence of a mature pharmacovigilance quality system.
GVP Audit Types
Flexible Audit Scope Based on Product, Process and Safety Risk
Audit scope can focus on the overall pharmacovigilance system, a specific process, affiliate, vendor, partner or urgent safety concern.
PV System Audits
Independent assessment of the pharmacovigilance quality system, governance, responsibilities, documentation and oversight framework.
- Pharmacovigilance governance
- Roles and responsibilities
- Quality system and SOP framework
- Training, deviations and CAPA
- Management review and performance metrics
Case Processing Audits
Evaluation of adverse event intake, triage, data entry, medical review, follow-up, quality control and reporting processes.
- Case intake and source handling
- Seriousness and expectedness assessment
- Medical review and coding
- Follow-up and quality control
- Expedited reporting timeliness
Signal Management Audits
Assessment of signal detection, validation, prioritization, assessment, escalation, documentation and closure.
- Signal detection methodology
- Validation and prioritization
- Medical and safety assessment
- Governance and escalation
- Signal documentation and closure
Aggregate Report Audits
Independent review of data collection, analysis, authoring, reconciliation, review and submission controls supporting aggregate safety reports.
- Data sourcing and reconciliation
- Benefit-risk evaluation
- Report authoring and review
- Submission planning and timeliness
- Quality control and approval
Vendor, Affiliate and Partner Audits
Qualification and oversight audits for pharmacovigilance vendors, affiliates, licensing partners and other organizations performing delegated safety activities.
- Safety data exchange responsibilities
- Quality agreements and governance
- Case and data reconciliation
- Performance metrics and escalation
- Deviation and CAPA follow-up
For-Cause GVP Audits
Focused independent review where serious safety, compliance, data integrity or oversight concerns require urgent and confidential assessment.
- Late reporting and case backlog
- Signal management concerns
- Safety data integrity issues
- Vendor or partner performance failure
- Independent investigation support
Audit Scope
Areas Commonly Evaluated During a GVP Audit
The final audit scope is adapted to the product portfolio, safety organization, global operating model, delegated activities, known risks and business objective.
Governance and Responsibilities
- Organizational accountability
- Role clarity and escalation
- Safety governance committees
- Decision documentation
- Management oversight
Case Management
- Adverse event intake
- Case triage and processing
- Medical review and coding
- Follow-up activities
- Reporting timelines
Signal Management
- Signal detection
- Validation and prioritization
- Assessment and documentation
- Escalation and decision-making
- Closure and tracking
Aggregate Reporting
- Data collection and reconciliation
- Benefit-risk analysis
- Authoring and review
- Submission planning
- Quality control and approval
Vendor and Partner Oversight
- Qualification and due diligence
- Safety data exchange agreements
- Performance monitoring
- Reconciliation and escalation
- Audit and CAPA follow-up
PV Quality System
- SOP and document control
- Training and qualification
- Deviation and CAPA systems
- Quality metrics and management review
- Inspection readiness
Audit Process
A Structured GVP Audit From Planning to Follow-Up
The process is designed to provide objective findings, clear risk classification and practical recommendations for pharmacovigilance, quality and executive teams.
Context and Scope Review
Understand the product portfolio, PV organization, vendor model, previous findings, inspection exposure and business purpose of the audit.
Risk-Based Planning
Define criteria, documentation needs, sampling strategy, interviewees and high-risk safety processes requiring deeper review.
Pre-Audit Document Review
Review procedures, quality records, safety agreements, metrics, reports, case samples and available oversight documentation.
Audit Execution
Conduct interviews, process walkthroughs, system demonstrations, record sampling and evidence-based review of safety activities.
Finding Evaluation
Assess significance, recurrence, systemic impact and potential effect on patient safety, reporting compliance and benefit-risk governance.
Reporting and Follow-Up
Deliver risk-ranked findings, recommendations and optional CAPA review or effectiveness verification support.
Deliverables
Clear Outputs for Safety, Quality and Leadership Teams
Deliverables can be adapted to routine assurance, vendor qualification, inspection readiness, due diligence or for-cause review.
Audit Plan
- Audit objectives and scope
- Applicable criteria
- Processes and organizations included
- Document request list
- Audit schedule and interview plan
Audit Report
- Executive summary
- Evidence-based observations
- Risk classification
- Systemic and recurring themes
- Recommended next steps
Leadership Risk Summary
- Material safety concerns
- Compliance and reporting risks
- Vendor and oversight weaknesses
- Inspection exposure
- Priority decisions and actions
CAPA Review Support
- Root cause challenge
- Action adequacy review
- Risk reduction assessment
- Evidence expectations
- Closure-readiness considerations
Follow-Up Audit
- CAPA implementation review
- Evidence verification
- Repeat finding assessment
- Residual risk review
- Effectiveness verification
Inspection Readiness Summary
- Critical readiness gaps
- Priority safety and system risks
- PV and leadership actions
- Document readiness considerations
- Final readiness priorities
When GVP Audits Are Most Valuable
Common Pharmacovigilance Audit Scenarios
GVP audits can support routine quality assurance, vendor oversight, inspection preparation, due diligence or urgent independent review.
Vendor Qualification
A pharmacovigilance service provider requires assessment before selection, renewal or expanded responsibilities.
Upcoming PV Inspection
The organization needs independent assurance over system, process, vendor and documentation readiness.
Case Backlog or Late Reporting
Timeliness, workload, quality or escalation concerns require focused independent review.
Signal Management Concern
Signal detection, assessment, governance or documentation requires independent evaluation.
Partner Oversight Gap
Responsibilities, reconciliations, performance monitoring or escalation with a partner are not sufficiently controlled.
New Product or Portfolio Growth
The pharmacovigilance system must scale to support new products, markets, affiliates or safety obligations.
Transaction Due Diligence
A product, company, partner or acquisition target requires safety system and compliance-risk assessment.
For-Cause Investigation
Serious safety, reporting or data concerns require confidential and targeted independent assurance.
Business Value
Protect Patients, Safety Data and Regulatory Confidence
Independent GVP audits help organizations identify weaknesses earlier, strengthen safety governance and improve confidence in reporting, oversight and benefit-risk decision-making.
Stronger Patient Safety Oversight
Identify weaknesses in case processing, signal management and safety escalation before they create significant regulatory exposure.
More Reliable Safety Data
Improve confidence that safety records are complete, timely, traceable and supported by controlled processes.
More Effective Third-Party Control
Strengthen vendor, affiliate and partner governance through clearer responsibilities, metrics, reconciliation and escalation.
FAQ
GVP Audit Questions
Common questions from pharmaceutical, biotechnology, safety and quality organizations considering independent GVP audit support.
Can GVP audits be conducted remotely?
Yes. Depending on the scope, documentation and system access, pharmacovigilance system, process, vendor and partner audits can be delivered remotely, onsite or through a hybrid model.
Can the audit focus on one specific PV process?
Yes. The scope can focus on case processing, signal management, aggregate reporting, vendor oversight, reconciliations, safety agreements, deviations, CAPA or another defined process.
Can you audit a pharmacovigilance vendor or partner?
Yes. Qualification, requalification and oversight audits can be conducted for pharmacovigilance vendors, affiliates, licensing partners and service providers.
Can you support inspection readiness?
Yes. Support can include gap assessment, mock inspection preparation, document readiness, SME coaching, vendor oversight review and remediation prioritization.
Can you support CAPA development after the audit?
Yes. Support can include root cause review, CAPA adequacy assessment, remediation planning and follow-up effectiveness verification.
Is NDA-based collaboration available?
Yes. GVP audit engagements are handled confidentially, and NDA-based collaboration can be used where required.